Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood pressure drug tested for long-term safety in 323 patients

NCT ID NCT07543120

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This study looks at the long-term safety and effectiveness of the drug QCZ484 in people with high blood pressure. It is for patients who already completed a previous study with the same drug. Researchers will monitor side effects and track blood pressure changes over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 323 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Nov 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Successful completion of treatment period on QCZ484 study medication in parent study. 3. No significant safety issue that may place participant at safety risk as determined by the Investigator. Exclusion Criteria: Participants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study: 1. Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator. 2. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study. 3. Permanent or persistent atrial fibrillation developed during the parent study. 4. Clinically significant valvular heart disease developed during the parent study. 5. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment. Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension (HTN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension (HTN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    25 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alliance for Multispecialty Research

    RECRUITING

    Wichita, Kansas, 67207, United States

  • American Research Centers of FL

    RECRUITING

    Pembroke Pines, Florida, 33027, United States

  • Anderson Medical Research

    RECRUITING

    Ft. Washington, Maryland, 20744, United States

    Contact Email: •••••@•••••

  • Cardiology Partners Clinical Research Institute

    RECRUITING

    Wellington, Florida, 33449, United States

  • Cen Exel FCR

    RECRUITING

    Tampa, Florida, 33613, United States

  • CenExel HRI

    RECRUITING

    Berlin, New Jersey, 08009, United States

  • Clinical Neuroscience Solutions Inc

    RECRUITING

    Memphis, Tennessee, 38119, United States

  • Clinical Research of Brandon LLC

    RECRUITING

    Brandon, Florida, 33511, United States

  • Conrad Clinical Research

    RECRUITING

    Edmond, Oklahoma, 73013, United States

  • Downtown L A Research Center Inc

    RECRUITING

    Los Angeles, California, 90017, United States

  • Eagle Clinical Research

    RECRUITING

    Chicago, Illinois, 60621, United States

  • Entrust Clinical Research

    RECRUITING

    Miami, Florida, 33176, United States

  • Inpatient Research Clinical LLC

    RECRUITING

    Miami Lakes, Florida, 33014, United States

  • Javara Research

    RECRUITING

    Fayetteville, Georgia, 30214, United States

  • Jefferson City Medical Group

    RECRUITING

    Jefferson City, Missouri, 65109, United States

  • Monroe Biomedical Research

    RECRUITING

    Monroe, North Carolina, 28112, United States

  • NICRs Research Center

    RECRUITING

    Garden Grove, California, 92844, United States

  • Novartis Investigative Site

    RECRUITING

    Suita, Osaka, 5650853, Japan

  • Novartis Investigative Site

    RECRUITING

    Chuo Ku, Tokyo, 104-0031, Japan

  • Novartis Investigative Site

    RECRUITING

    Chuo-ku, Tokyo, 1030027, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 160-0008, Japan

  • Novartis Investigative Site

    RECRUITING

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    RECRUITING

    Singapore, 529889, Singapore

  • Oakland Medical Research Center

    RECRUITING

    Troy, Michigan, 48085, United States

  • Sun Research Institute

    RECRUITING

    San Antonio, Texas, 78205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.